Company Quick10K Filing
Biogen Idec
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 194 $46,443
10-Q 2019-07-24 Quarter: 2019-06-30
10-Q 2019-04-24 Quarter: 2019-03-31
10-K 2019-02-06 Annual: 2018-12-31
10-Q 2018-10-23 Quarter: 2018-09-30
10-Q 2018-07-24 Quarter: 2018-06-30
10-Q 2018-04-24 Quarter: 2018-03-31
10-K 2018-02-01 Annual: 2017-12-31
10-Q 2017-10-24 Quarter: 2017-09-30
10-Q 2017-07-25 Quarter: 2017-06-30
10-Q 2017-04-25 Quarter: 2017-03-31
10-K 2017-02-02 Annual: 2016-12-31
10-Q 2016-10-26 Quarter: 2016-09-30
10-Q 2016-07-21 Quarter: 2016-06-30
10-Q 2016-04-21 Quarter: 2016-03-31
10-K 2016-02-03 Annual: 2015-12-31
10-Q 2015-10-21 Quarter: 2015-09-30
10-Q 2015-07-24 Quarter: 2015-06-30
10-Q 2015-04-24 Quarter: 2015-03-31
10-K 2015-02-04 Annual: 2014-12-31
10-Q 2014-10-22 Quarter: 2014-09-30
10-Q 2014-07-23 Quarter: 2014-06-30
10-K 2014-02-06 Annual: 2013-12-31
10-Q 2013-10-28 Quarter: 2013-09-30
10-Q 2013-07-25 Quarter: 2013-06-30
10-Q 2013-04-25 Quarter: 2013-03-31
10-K 2013-02-05 Annual: 2012-12-31
10-Q 2012-10-25 Quarter: 2012-09-30
10-Q 2012-07-24 Quarter: 2012-06-30
10-Q 2012-05-01 Quarter: 2012-03-31
10-K 2012-02-03 Annual: 2011-12-31
10-Q 2011-10-28 Quarter: 2011-09-30
10-Q 2011-07-26 Quarter: 2011-06-30
10-Q 2011-04-21 Quarter: 2011-03-31
10-K 2011-02-04 Annual: 2010-12-31
10-Q 2010-10-26 Quarter: 2010-09-30
10-Q 2010-07-20 Quarter: 2010-06-30
10-Q 2010-04-20 Quarter: 2010-03-31
10-K 2010-02-09 Annual: 2009-12-31
8-K 2019-12-19 Other Events
8-K 2019-09-29 Officers, Regulation FD, Other Events, Exhibits
8-K 2019-07-23 Earnings, Exhibits
8-K 2019-06-19 Shareholder Vote
8-K 2019-05-09 Officers
8-K 2019-04-29 Other Events, Exhibits
8-K 2019-04-24 Earnings, Exhibits
8-K 2019-03-24 Other Events
8-K 2019-01-29 Earnings, Exhibits
8-K 2018-11-01 Officers
8-K 2018-10-23 Earnings, Exhibits
8-K 2018-08-03 Other Events
8-K 2018-07-24 Earnings, Exhibits
8-K 2018-06-21 Officers
8-K 2018-06-12 Shareholder Vote
8-K 2018-04-24 Earnings, Exhibits
8-K 2018-01-25 Earnings, Exhibits

Biogen Idec Financials

BIIB Metrics, Comps, Filings

Annual | Quarterly

Business

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.

Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in this report.

We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Gilead Sciences (GILD) 85,862 79% 9.9 9% 63,210 40,594 22,357 17,630 5,957 10,182 100,705
Biogen Idec (BIIB) 46,443 86% 6.4 20% 26,288 13,339 14,072 12,044 5,294 7,912 50,669
Seattle Genetics (SGEN) 10,884 0% -42.0 -18% 1,568 296 758 0 -280 -258 10,820
Neurocrine Biosciences (NBIX) 8,009 99% 142.2 2% 1,067 583 605 599 18 55 7,862
Bio-Techne (TECH) 7,914 66% 38.0 5% 1,884 719 714 473 96 218 8,306
Qiagen (QGEN) 7,622 0% 5,748 3,113 0 0 0 0 8,637
Bluebird Bio (BLUE) 6,843 97% -10.2 -32% 2,023 387 57 55 -655 -638 6,507
Moderna (MRNA) 4,732 0% -18.0 -16% 1,685 347 65 0 -268 -253 4,568
Autolus Therapeutics (AUTL) 3,969 0% -161.3 -8% 254 22 0 0 -21 -23 3,752
Spark Therapeutics (ONCE) 3,953 37% -16.7 -31% 750 349 58 21 -231 -229 3,827
Repligen (RGEN) 3,939 56% 65.1 2% 1,068 189 233 129 27 57 3,721
Argenx (ARGX) 3,491 0% 578 40 0 0 0 0 3,489
Allogene Therapeutics (ALLO) 3,175 -17.8 -20% 734 78 0 0 -147 -142 2,524
China Biologic Products (CBPO) 2,933 64% 30.5 3% 2,010 165 186 119 69 85 2,594
Iovance Biotherapeutics (IOVA) 2,693 -15.2 -35% 436 39 0 0 -151 -150 2,289
Mesoblast (MESO) 2,543 0% 652 171 0 0 0 0 2,543
Adaptimmune Therapeutics (ADAP) 2,516 0% -27.2 -42% 240 53 42 0 -99 -91 2,477
Halozyme Therapeutics (HALO) 2,380 52% -91.6 -10% 418 158 182 95 -43 -25 2,327
Genetic Technologies (GENE) 2,362 0% 6 1 0 0 0 0 2,357
Crispr Therapeutics (CRSP) 2,350 0% -9.8 -41% 494 127 2 0 -200 -196 1,918

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash5827605155716031,2051,3082,3261,5741,225
Accounts Receivable5516055856878241,2921,2271,4421,7871,958
Inventory2943274476598048931,002903930
PP&E1,6371,6421,5711,7422,8691,7662,1882,5023,1823,601
Assets8,5528,0929,05010,13011,86314,31719,50522,87723,65325,289
Accounts Payable119163186204220229267280396370
Long-Term Debt1,0801,0661,0616875685636,5606,5566,0036,000
Liabilities2,2902,6432,6233,1663,2423,50310,13010,74811,05412,257
Stockholders' Equity6,2225,3976,4256,9628,62010,8099,37312,14012,61313,040
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue3,1533,4703,8364,1665,5428,2039,1889,81810,35513,453
Cost of Revenue382400467545-532-329-335-152-2891,816
Gross Profit2,7714,3164,5824,9716,0748,5329,5239,97010,64411,637
R&D1,2831,2491,2201,3351,4441,8932,0131,9732,2542,597
SG&A9111,0321,0561,2771,7122,2322,1131,9481,9362,106
Tax3563314454716011,1631,6751,6422,4591,426
Net Income9778991,2671,3801,8622,9423,5933,6962,6704,474
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating1,0751,6251,7281,8802,3452,9423,7164,5224,5516,188
Cash Investing-395345-1,650-950-1,605-1,543-4,554-2,485-2,963-2,046
Cash Financing-724-1,785-320-877-717-756986-988-2,380-4,472